A Study of MGC026 in Participants With Advanced Solid Tumors

• Research type

  Research Study

• Full title

  A Phase 1/1b, First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants with Advanced Solid Tumors

• IRAS ID

  1009258

• Contact name

  Kathryn Grossi

• Contact email

  grossik@macrogenics.com

• Sponsor organisation

  MacroGenics, Inc.

• Clinicaltrials.gov Identifier

  NCT06242470

• Research summary

  The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors. The study has a dose escalation portion and a cohort expansion portion of the study.
  Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood samples collected for research purposes.

• REC name

  London - City & East Research Ethics Committee

• REC reference

  24/LO/0265

• Date of REC Opinion

  7 May 2024

• REC opinion

  Further Information Favourable Opinion